Drew Blackstock, MD
Addiction Medicine · Bartlett, TNNPI 1841532819
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,867 of the $3,747 with a category attached, or 76.5%. 20 manufacturers reported payments, led by Medtronic at 38.2% of the total. Reporting peaked in 2022 at $1,676 and has fallen 61.9% since, to $639 in 2025. Among addiction medicine clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Collegium Pharmaceutical, Inc.$575
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$527
- Indivior Inc.$430
- GRT US Holding, Inc.$213
- Averitas Pharma Inc.$108
- plus $465 from 14 others
What the payments were for
- Travel & lodging$82122%
- Food & beverage$2,86777%
- Education$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $1,431 |
| Collegium Pharmaceutical, Inc. | 35 | $575 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $527 |
| Indivior Inc. | 21 | $430 |
| GRT US Holding, Inc. | 8 | $213 |
| Averitas Pharma Inc. | 6 | $108 |
| Braeburn Inc. | 3 | $54 |
| Alkermes, Inc. | 4 | $53 |
| Boston Scientific | 3 | $51 |
| Krystal Biotech Inc | 2 | $40 |
| Biodelivery Sciences International, Inc. | 3 | $38 |
| MDD US Operations, LLC | 3 | $37 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Convatec Inc. | 1 | $34 |
| AbbVie | 2 | $34 |
| IBSA Pharma Inc. | 2 | $33 |
| Si-bone, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $15 |
| SPR Therapeutics, Inc | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$970
How this compares
$3,747 in reported general payments places this provider in the 90th percentile of 76 addiction medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 143 | $125,472 |
| LinzessLinaclotide | 68 | $41,061 |
| Buprenorphine | 121 | $29,274 |
| Xtampza ErOxycodone Myristate | 33 | $26,828 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 936 | $23,781 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $21,992 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 715 | $19,130 |
| OxycontinOxycodone Hcl | 21 | $17,612 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 238 | $12,357 |
| MovantikNaloxegol Oxalate | 22 | $8,918 |
| Nucynta ErTapentadol Hcl | 12 | $7,288 |
| Gabapentin | 585 | $6,288 |
| Pregabalin | 289 | $5,182 |
| Methocarbamol | 258 | $3,431 |
| Cyclobenzaprine Hcl | 231 | $2,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er | $575 | $159,589188 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl | $35 | $43,536405 claims |
| AbbVieLinzess | $34 | $41,06168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 76 addiction medicine providers in Tennessee.
Other addiction medicine in Bartlett
- Shawn HammBartlett$2K
- John Rocco RodneyMemphis$251K
- Marie-Louise MengNashville$19K
- David McCordFranklin$14K
- Kimberly CollinsAntioch$6K
- Joshua HareChattanooga$5K
- Karen AveryHixson$4K
- Winston GrinerNashville$4K
- Richard SoperNashville$2K
- Steve WeaverJackson$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.